Figure 2
Figure 2. Autologous Transplantation in High Risk Patients with DLBCL. (A) The disease-free survival of patients who had 2 or 3 adverse risk factors in the age-adjusted IPI who responded to ACVBP and were randomly allocated to autologous transplant or consolidation with further chemotherapy. Adapted with permission from J Clin Oncol. Copyright 2000.70 (B) Progression-free survival (PFS) for 56 high-risk patients in first remission after an anthracycline-containing chemotherapy regimen undergoing autotransplantation at the University of Nebraska Medical Center.

Autologous Transplantation in High Risk Patients with DLBCL. (A) The disease-free survival of patients who had 2 or 3 adverse risk factors in the age-adjusted IPI who responded to ACVBP and were randomly allocated to autologous transplant or consolidation with further chemotherapy. Adapted with permission from J Clin Oncol. Copyright 2000.70  (B) Progression-free survival (PFS) for 56 high-risk patients in first remission after an anthracycline-containing chemotherapy regimen undergoing autotransplantation at the University of Nebraska Medical Center.

Close Modal

or Create an Account

Close Modal
Close Modal